SBIR-STTR Award

Gene Expression Data Analysis for Clinical Research
Award last edited on: 10/17/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCHGR
Total Award Amount
$171,674
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Lue Ping Zhao

Company Information

Enodar Biologic Corporation (AKA: Enodar Biometric Corporation)

1100 Olive Way Suite 900
Seattle, WA 98101
   (206) 344-3300
   enodar@enodar.com
   www.enodar.com
Location: Single
Congr. District: 07
County: King

Phase I

Contract Number: 1R43HG002572-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2002
Phase I Amount
$171,674
Our long-term goal for our newly formed bioinformatics company Enodar BioLogic Corporation (EBC) is to bring rigorously developed statistical tools to clinical genomic studies by marketing a software module called GENECLINIC. In the short-term, we will investigate the performance of a regression manifold of heterogeneous generalized linear models (HGLMs) in clinical genomic studies. If promising, we will develop HGLMs into a working prototype of GENECLINIC. GENECLINIC will associate gene expression with clinical outcomes, facilitating discovery of biomarkers for assessing efficacy of clinical treatment and prognosis. Phase I specific aims are to: 1) develop and test HGLMs for modeling clinical outcomes with expression profiles and 2) develop a user-friendly GENECLINIC software prototype module. GENECLINIC will have a key advantage over visualization tools and clustering methods by enabling clinical investigators to postulate and test specific genome-wide hypotheses under rigorous statistical assessment.

Thesaurus Terms:
clinical research, computer data analysis, computer program /software, computer system design /evaluation, gene expression, genetic mapping, informatics, prognosis computer human interaction, computer simulation, mathematical model, microarray technology, statistics /biometry human genetic material tag

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----